1/3/2020

Leuprolide Acetate Long-Acting Suspension for Intramuscular Injection

Reason for the Shortage

- Abbvie states Lupron Depot was on shortage due to a routine manufacturing compliance review.
- Lupron Depot-Ped products are not included in this posting.

Available Products

- Lupron Depot intramuscular powder for suspension for injection, AbbVie, 11.25 mg (3 month), single dose administration kit, dual chamber prefilled syringe, 1 count, NDC 00074-3663-03
- Lupron Depot intramuscular powder for suspension for injection, AbbVie, 3.75 mg (1 month), single dose administration kit, dual chamber prefilled syringe, 1 count, NDC 00074-3641-03
- Lupron Depot intramuscular powder for suspension for injection, AbbVie, 22.5 mg (3 month), single dose administration kit, dual chamber prefilled syringe, 1 count, NDC 00074-3346-03
- Lupron Depot intramuscular powder for suspension for injection, AbbVie, 30 mg (4 month), single dose administration kit, dual chamber prefilled syringe, 1 count, NDC 00074-3683-03
- Lupron Depot intramuscular powder for suspension for injection, AbbVie, 45 mg (6 month), single dose administration kit, dual chamber prefilled syringe, 1 count, NDC 00074-3473-03
- Lupron Depot intramuscular powder for suspension for injection, AbbVie, 7.5 mg (1 month), single dose administration kit, dual chamber prefilled syringe, 1 count, NDC 00074-3642-03

Implications for Patient Care

- Lupron Depot 3.75 mg and 11.25 mg prefilled syringe kits are labeled for the management of endometriosis and for anemia, in combination with iron therapy, prior to uterine fibroid surgery.[1]
- Lupron Depot 7.5 mg, 22.5 mg, 30 mg, and 45 mg prefilled syringe kits are labeled for the palliative treatment of advanced prostate cancer.[1]

References

1. Leuprolide. Lexi-Drugs Online. Hudson, OH: Lexi-Comp, Inc. 2019.

Updated

Updated January 3, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. Created December 5, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.